BERGENBIO ASA: Invitation to second quarter and half year 2022 results webcast
Bergen, Norway, 9 August 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL inhibitors for severe unmet medical needs, will be announcing its results for the second quarter and half year 2022 on Tuesday 23 August 2022. The briefing will take place at 10:00 am CET at:Carnegie AS, Fjordalleen 16, Aker Brygge, 5th Floor, Oslowhere BerGenBio's senior management team will provide an update on the Company followed by a Q&A session. To attend in person please register by mail toir@bergenbio.com The presentation will webcast live